Sterling Capital Management’s X4 Pharmaceuticals XFOR Stock Holding History

Sterling Capital Management’s Portfolio XFOR Stock Details XFOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$4.79K	Buy	1,652 +23	+1%	+$89	﹤0.01%	2879
2026 Q2	$7.61K	Buy	+1,629	New	+$6.68K	﹤0.01%	2379
2025 Q2	–	Sell	-6	Closed	-$41	–	3412
2025 Q1	$41	Hold	6	–	–	﹤0.01%	3184
2024 Q4	$126	Hold	6	–	–	﹤0.01%	3162
2024 Q3	$115	Buy	+6	New	+$125	﹤0.01%	3179

Other funds holding XFOR

Pettinga Financial Advisors Evansville, Indiana $606M AUM 15.91% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Blue Trust Inc Alpharetta, Georgia $9.5B AUM 13.02% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

Sterling Capital Management's XFOR Position: Q3 2026 in Review

Sterling Capital Management increased its X4 Pharmaceuticals (XFOR) stake by 1.4% in Q3 2026, buying an estimated $89 and bringing the position to 1,652 shares worth $4.79K. The position accounts for ﹤0.01% of the portfolio, ranked #2879.

Sterling Capital Management first reported a position in XFOR in Q3 2024 and has held it in 5 quarters since. The position peaked at $7.61K in Q2 2026. 7 funds tracked by Wall St. Rank hold XFOR as of Q3 2026.

Sterling Capital Management held 1,652 shares of X4 Pharmaceuticals worth $4.79K as of Q3 2026.
Sterling Capital Management bought 23 X4 Pharmaceuticals shares in Q3 2026, an estimated $89.
X4 Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2879 holding.
Sterling Capital Management first reported a position in X4 Pharmaceuticals in Q3 2024 and has held it in 5 quarters since.
Sterling Capital Management's X4 Pharmaceuticals position peaked at $7.61K in Q2 2026.
7 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.